Gain expert insight into the emerging role of NRG1 fusions as rare oncogenic drivers in a variety of solid tumors and learn about the targeted therapies in development from expert commentaries, a text-based module, and a downloadable slideset.
Learn how experts detect and treat NRG1 fusion–positive solid tumors in this interactive text module with expert perspectives from Stephen V. Liu, MD, and Ryma Benayed, PhD, on applying emerging research to biomarker testing and treatment strategies for patients with NRG1 fusion–driven cancers.
Read this commentary from Maria E. Arcila, MD, on the recommendations for testing for NRG1 fusions in patients with solid tumors.
Expert commentary by Joshua Sabari, MD, on the role of NRG1 fusions in solid tumors and the emerging targeted therapies for patients harboring this oncogenic alteration.
Review this slideset on applying emerging research to biomarker testing and treatment strategies for patients with NRG1 fusion–driven cancers by Stephen V. Liu, MD, and Ryma Benayed, PhD.
Clinical Care Options (CCO): expert opinions from Drs Stephen Liu, Maria Arcila, Dr. Ryma Benayed on testing and targeting NRG1 fusions